| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 14 | 2017 | 219 | 1.940 |
Why?
|
| Image Processing, Computer-Assisted | 19 | 2023 | 689 | 1.730 |
Why?
|
| Brain Neoplasms | 14 | 2018 | 371 | 1.680 |
Why?
|
| Machine Learning | 12 | 2023 | 170 | 1.630 |
Why?
|
| Magnetic Resonance Imaging | 18 | 2019 | 2223 | 1.420 |
Why?
|
| Skin Neoplasms | 9 | 2022 | 375 | 1.380 |
Why?
|
| Dermoscopy | 6 | 2022 | 14 | 1.240 |
Why?
|
| Brain | 9 | 2019 | 2176 | 1.060 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 5 | 2010 | 24 | 1.040 |
Why?
|
| Diffusion Tensor Imaging | 8 | 2015 | 211 | 1.030 |
Why?
|
| Alzheimer Disease | 3 | 2023 | 565 | 1.010 |
Why?
|
| Pyrimidines | 5 | 2010 | 178 | 0.950 |
Why?
|
| Software | 6 | 2020 | 418 | 0.940 |
Why?
|
| Neural Pathways | 7 | 2015 | 324 | 0.930 |
Why?
|
| Brain Mapping | 9 | 2015 | 532 | 0.900 |
Why?
|
| Genomics | 10 | 2019 | 168 | 0.880 |
Why?
|
| Image Interpretation, Computer-Assisted | 10 | 2020 | 237 | 0.880 |
Why?
|
| Nerve Block | 2 | 2019 | 55 | 0.800 |
Why?
|
| Lymphangioma, Cystic | 1 | 2021 | 3 | 0.760 |
Why?
|
| Airway Obstruction | 1 | 2021 | 49 | 0.730 |
Why?
|
| Emergence Delirium | 1 | 2020 | 4 | 0.720 |
Why?
|
| Workplace Violence | 1 | 2020 | 8 | 0.710 |
Why?
|
| Physostigmine | 1 | 2020 | 14 | 0.710 |
Why?
|
| Melanoma | 6 | 2022 | 335 | 0.700 |
Why?
|
| Myotomy | 1 | 2019 | 14 | 0.690 |
Why?
|
| Nervous System | 1 | 2019 | 45 | 0.680 |
Why?
|
| Esophageal Achalasia | 1 | 2019 | 78 | 0.670 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 102 | 0.660 |
Why?
|
| Database Management Systems | 2 | 2016 | 25 | 0.650 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2019 | 88 | 0.640 |
Why?
|
| Dogs | 1 | 2019 | 490 | 0.630 |
Why?
|
| Neoplasms | 5 | 2020 | 1667 | 0.630 |
Why?
|
| Medical Informatics | 2 | 2016 | 71 | 0.630 |
Why?
|
| Pain, Postoperative | 2 | 2019 | 214 | 0.620 |
Why?
|
| Libraries, Digital | 1 | 2017 | 2 | 0.610 |
Why?
|
| Databases, Factual | 5 | 2016 | 622 | 0.600 |
Why?
|
| Humans | 70 | 2023 | 68618 | 0.590 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2017 | 75 | 0.540 |
Why?
|
| Behavior, Animal | 5 | 2019 | 470 | 0.500 |
Why?
|
| Reproducibility of Results | 10 | 2022 | 2077 | 0.490 |
Why?
|
| Data Collection | 1 | 2016 | 420 | 0.480 |
Why?
|
| Atlases as Topic | 2 | 2013 | 5 | 0.480 |
Why?
|
| Anti-Anxiety Agents | 3 | 2010 | 107 | 0.470 |
Why?
|
| Algorithms | 9 | 2020 | 1196 | 0.470 |
Why?
|
| Biomarkers, Tumor | 8 | 2018 | 508 | 0.460 |
Why?
|
| Biomedical Research | 2 | 2020 | 310 | 0.460 |
Why?
|
| Internet | 4 | 2019 | 390 | 0.460 |
Why?
|
| Neoplasm Proteins | 2 | 2015 | 307 | 0.460 |
Why?
|
| Glioma | 5 | 2018 | 140 | 0.450 |
Why?
|
| Pathology, Clinical | 1 | 2013 | 16 | 0.450 |
Why?
|
| Artificial Intelligence | 4 | 2022 | 159 | 0.430 |
Why?
|
| Gyrus Cinguli | 3 | 2012 | 113 | 0.420 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2014 | 239 | 0.420 |
Why?
|
| Olfactory Pathways | 1 | 2012 | 9 | 0.410 |
Why?
|
| Manganese Compounds | 1 | 2012 | 8 | 0.410 |
Why?
|
| Chlorides | 1 | 2012 | 68 | 0.410 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 848 | 0.410 |
Why?
|
| Deep Brain Stimulation | 2 | 2012 | 71 | 0.400 |
Why?
|
| Reflex, Startle | 2 | 2012 | 39 | 0.390 |
Why?
|
| Contrast Media | 4 | 2014 | 595 | 0.390 |
Why?
|
| Crowdsourcing | 2 | 2022 | 8 | 0.380 |
Why?
|
| Computer Simulation | 3 | 2013 | 706 | 0.380 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 2 | 2013 | 51 | 0.370 |
Why?
|
| Male | 32 | 2022 | 37321 | 0.370 |
Why?
|
| Female | 33 | 2022 | 38074 | 0.370 |
Why?
|
| Histological Techniques | 3 | 2019 | 10 | 0.350 |
Why?
|
| Internal Capsule | 1 | 2008 | 7 | 0.330 |
Why?
|
| Hydrocortisone | 3 | 2013 | 291 | 0.330 |
Why?
|
| Swimming | 1 | 2008 | 38 | 0.310 |
Why?
|
| Social Behavior | 3 | 2015 | 164 | 0.310 |
Why?
|
| Prognosis | 10 | 2020 | 2093 | 0.310 |
Why?
|
| Skin | 4 | 2021 | 451 | 0.310 |
Why?
|
| Adult | 21 | 2021 | 21403 | 0.300 |
Why?
|
| Fear | 3 | 2014 | 239 | 0.290 |
Why?
|
| White Matter | 3 | 2014 | 174 | 0.290 |
Why?
|
| Breast Neoplasms | 4 | 2022 | 1536 | 0.290 |
Why?
|
| Animals | 18 | 2019 | 20881 | 0.280 |
Why?
|
| Motor Activity | 2 | 2018 | 621 | 0.280 |
Why?
|
| Amyloid beta-Peptides | 2 | 2020 | 191 | 0.280 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2006 | 21 | 0.270 |
Why?
|
| Cerebral Cortex | 4 | 2013 | 415 | 0.260 |
Why?
|
| Datasets as Topic | 4 | 2020 | 53 | 0.260 |
Why?
|
| Doxapram | 1 | 2005 | 2 | 0.250 |
Why?
|
| Breeding | 2 | 2019 | 15 | 0.250 |
Why?
|
| Cell Nucleus | 3 | 2022 | 305 | 0.250 |
Why?
|
| Depressive Disorder | 1 | 2008 | 621 | 0.240 |
Why?
|
| Panic Disorder | 1 | 2005 | 121 | 0.240 |
Why?
|
| Middle Aged | 15 | 2019 | 21147 | 0.240 |
Why?
|
| Stress, Psychological | 3 | 2013 | 824 | 0.230 |
Why?
|
| Genome, Human | 2 | 2014 | 62 | 0.230 |
Why?
|
| Nevus | 3 | 2019 | 17 | 0.230 |
Why?
|
| Morphine | 2 | 2018 | 76 | 0.220 |
Why?
|
| Young Adult | 10 | 2021 | 5717 | 0.220 |
Why?
|
| Endocrine System | 1 | 2003 | 11 | 0.220 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2015 | 627 | 0.220 |
Why?
|
| Central Nervous System Stimulants | 1 | 2005 | 221 | 0.210 |
Why?
|
| Stress, Physiological | 2 | 2007 | 215 | 0.210 |
Why?
|
| Mutation | 4 | 2016 | 1213 | 0.210 |
Why?
|
| Bone Marrow | 1 | 2023 | 168 | 0.200 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2014 | 1506 | 0.200 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2010 | 2083 | 0.200 |
Why?
|
| Social Environment | 1 | 2003 | 182 | 0.200 |
Why?
|
| Hippocampus | 3 | 2014 | 471 | 0.200 |
Why?
|
| Dermatologists | 2 | 2019 | 5 | 0.190 |
Why?
|
| Psychomotor Performance | 2 | 2013 | 213 | 0.190 |
Why?
|
| Nerve Net | 2 | 2019 | 181 | 0.190 |
Why?
|
| Species Specificity | 2 | 2019 | 303 | 0.190 |
Why?
|
| Allografts | 1 | 2021 | 63 | 0.190 |
Why?
|
| Uterus | 1 | 2021 | 77 | 0.180 |
Why?
|
| Attention | 2 | 2013 | 225 | 0.180 |
Why?
|
| Workflow | 2 | 2023 | 100 | 0.180 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2020 | 1 | 0.180 |
Why?
|
| Sensitivity and Specificity | 4 | 2020 | 1753 | 0.180 |
Why?
|
| Lewy Body Disease | 1 | 2020 | 9 | 0.180 |
Why?
|
| Pan troglodytes | 3 | 2014 | 6 | 0.180 |
Why?
|
| Cesarean Section | 1 | 2021 | 101 | 0.180 |
Why?
|
| Gene Expression Profiling | 5 | 2016 | 498 | 0.180 |
Why?
|
| Rats | 8 | 2014 | 5300 | 0.180 |
Why?
|
| Dermatology | 1 | 2022 | 75 | 0.180 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2019 | 7 | 0.170 |
Why?
|
| Predatory Behavior | 1 | 2019 | 10 | 0.170 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2019 | 24 | 0.170 |
Why?
|
| Pathology | 1 | 2019 | 17 | 0.170 |
Why?
|
| STAT1 Transcription Factor | 1 | 2019 | 35 | 0.170 |
Why?
|
| Gestational Age | 1 | 2021 | 389 | 0.170 |
Why?
|
| Pigmentation Disorders | 1 | 2019 | 11 | 0.170 |
Why?
|
| Body Size | 1 | 2019 | 39 | 0.170 |
Why?
|
| Skull | 1 | 2019 | 63 | 0.170 |
Why?
|
| Computational Biology | 2 | 2011 | 190 | 0.170 |
Why?
|
| Maze Learning | 2 | 2010 | 138 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2015 | 786 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 300 | 0.160 |
Why?
|
| Organ Size | 1 | 2019 | 242 | 0.160 |
Why?
|
| Aged | 7 | 2017 | 14862 | 0.160 |
Why?
|
| Models, Statistical | 3 | 2012 | 448 | 0.160 |
Why?
|
| Labor Pain | 1 | 2018 | 1 | 0.160 |
Why?
|
| Bone Marrow Cells | 1 | 2019 | 217 | 0.160 |
Why?
|
| Cesarean Section, Repeat | 1 | 2018 | 4 | 0.160 |
Why?
|
| Phylogeny | 1 | 2019 | 197 | 0.160 |
Why?
|
| Genes, Neoplasm | 2 | 2016 | 18 | 0.160 |
Why?
|
| Sentinel Lymph Node | 1 | 2018 | 4 | 0.160 |
Why?
|
| Anesthesia, Obstetrical | 1 | 2018 | 11 | 0.160 |
Why?
|
| Interferon-gamma | 1 | 2019 | 241 | 0.160 |
Why?
|
| Genetic Variation | 1 | 2019 | 220 | 0.160 |
Why?
|
| Anesthesia, Spinal | 1 | 2018 | 16 | 0.160 |
Why?
|
| Analgesia, Obstetrical | 1 | 2018 | 15 | 0.160 |
Why?
|
| Smell | 1 | 2019 | 131 | 0.160 |
Why?
|
| Genetic Markers | 2 | 2015 | 144 | 0.160 |
Why?
|
| Bupivacaine | 1 | 2018 | 27 | 0.160 |
Why?
|
| Survival Analysis | 6 | 2016 | 714 | 0.150 |
Why?
|
| Epinephrine | 1 | 2018 | 103 | 0.150 |
Why?
|
| Patient Safety | 1 | 2020 | 202 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 91 | 0.150 |
Why?
|
| Microvessels | 2 | 2017 | 43 | 0.150 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 33 | 0.150 |
Why?
|
| Lentigo | 1 | 2017 | 4 | 0.150 |
Why?
|
| Mental Disorders | 1 | 2003 | 659 | 0.150 |
Why?
|
| Survival | 1 | 2017 | 22 | 0.150 |
Why?
|
| Image Enhancement | 2 | 2015 | 143 | 0.150 |
Why?
|
| Phenotype | 6 | 2016 | 947 | 0.150 |
Why?
|
| Pregnancy | 2 | 2021 | 2334 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 3 | 2014 | 2791 | 0.150 |
Why?
|
| Anesthetics, Local | 1 | 2018 | 83 | 0.150 |
Why?
|
| Parietal Lobe | 2 | 2014 | 59 | 0.150 |
Why?
|
| Treatment Outcome | 6 | 2019 | 7029 | 0.150 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2010 | 106 | 0.140 |
Why?
|
| Proportional Hazards Models | 3 | 2014 | 792 | 0.140 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2015 | 333 | 0.140 |
Why?
|
| Frontal Lobe | 2 | 2014 | 156 | 0.140 |
Why?
|
| Survival Rate | 3 | 2014 | 1056 | 0.130 |
Why?
|
| Kidney | 1 | 2021 | 945 | 0.130 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 94 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 756 | 0.130 |
Why?
|
| DNA Methylation | 2 | 2016 | 193 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 445 | 0.130 |
Why?
|
| Proteomics | 1 | 2017 | 246 | 0.130 |
Why?
|
| Tumor Microenvironment | 2 | 2017 | 213 | 0.120 |
Why?
|
| Geniculate Bodies | 1 | 2014 | 10 | 0.120 |
Why?
|
| Genetic Techniques | 1 | 2015 | 32 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 446 | 0.120 |
Why?
|
| Histocytochemistry | 1 | 2015 | 149 | 0.120 |
Why?
|
| User-Computer Interface | 1 | 2016 | 230 | 0.120 |
Why?
|
| Time Factors | 4 | 2018 | 4655 | 0.120 |
Why?
|
| Analgesics, Opioid | 2 | 2018 | 498 | 0.120 |
Why?
|
| Anhedonia | 1 | 2014 | 15 | 0.120 |
Why?
|
| Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I | 1 | 2014 | 3 | 0.120 |
Why?
|
| Embolism | 1 | 2014 | 45 | 0.120 |
Why?
|
| Infant | 1 | 2021 | 2891 | 0.120 |
Why?
|
| Biological Evolution | 1 | 2014 | 86 | 0.120 |
Why?
|
| Prevalence | 2 | 2015 | 1619 | 0.120 |
Why?
|
| Cell Death | 1 | 2014 | 329 | 0.110 |
Why?
|
| Social Dominance | 1 | 2013 | 4 | 0.110 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2007 | 435 | 0.110 |
Why?
|
| Interpersonal Relations | 1 | 2015 | 209 | 0.110 |
Why?
|
| Systems Integration | 1 | 2013 | 30 | 0.110 |
Why?
|
| Gene Dosage | 1 | 2013 | 47 | 0.110 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2013 | 4 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 1173 | 0.110 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 839 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2016 | 374 | 0.110 |
Why?
|
| Gene Expression | 2 | 2013 | 770 | 0.100 |
Why?
|
| Imitative Behavior | 1 | 2012 | 4 | 0.100 |
Why?
|
| Brain Injuries | 1 | 2015 | 268 | 0.100 |
Why?
|
| Amygdala | 1 | 2014 | 159 | 0.100 |
Why?
|
| Movement | 1 | 2013 | 179 | 0.100 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1465 | 0.100 |
Why?
|
| Cells | 1 | 2012 | 7 | 0.100 |
Why?
|
| Mice | 3 | 2014 | 8474 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 48 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2013 | 141 | 0.100 |
Why?
|
| Decision Making | 1 | 2015 | 410 | 0.100 |
Why?
|
| Models, Biological | 2 | 2014 | 981 | 0.100 |
Why?
|
| Echo-Planar Imaging | 1 | 2011 | 17 | 0.100 |
Why?
|
| Bias | 1 | 2012 | 148 | 0.100 |
Why?
|
| Cell Count | 2 | 2023 | 248 | 0.090 |
Why?
|
| Adrenal Glands | 1 | 2010 | 46 | 0.090 |
Why?
|
| Genotype | 4 | 2014 | 786 | 0.090 |
Why?
|
| Septal Nuclei | 1 | 2010 | 31 | 0.090 |
Why?
|
| Up-Regulation | 2 | 2012 | 682 | 0.090 |
Why?
|
| Oligodendroglioma | 1 | 2010 | 18 | 0.090 |
Why?
|
| Risk Factors | 3 | 2015 | 5731 | 0.090 |
Why?
|
| Learning | 1 | 2012 | 186 | 0.090 |
Why?
|
| Signal Transduction | 5 | 2019 | 2689 | 0.090 |
Why?
|
| Protein Binding | 2 | 2019 | 1027 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2010 | 2550 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2014 | 4848 | 0.090 |
Why?
|
| Megakaryocytes | 1 | 2009 | 18 | 0.090 |
Why?
|
| Game Theory | 2 | 2015 | 7 | 0.090 |
Why?
|
| G1 Phase | 1 | 2009 | 42 | 0.090 |
Why?
|
| Bipolar Disorder | 1 | 2012 | 307 | 0.080 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2012 | 257 | 0.080 |
Why?
|
| MicroRNAs | 2 | 2015 | 447 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 334 | 0.080 |
Why?
|
| Cluster Analysis | 3 | 2015 | 219 | 0.080 |
Why?
|
| Prefrontal Cortex | 2 | 2012 | 640 | 0.080 |
Why?
|
| Rats, Inbred Strains | 1 | 2008 | 532 | 0.080 |
Why?
|
| Aging | 1 | 2014 | 911 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 137 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2019 | 108 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2022 | 7277 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 231 | 0.070 |
Why?
|
| ROC Curve | 2 | 2019 | 392 | 0.070 |
Why?
|
| Depressive Disorder, Major | 1 | 2012 | 439 | 0.070 |
Why?
|
| Exercise Test | 1 | 2008 | 242 | 0.070 |
Why?
|
| United States | 2 | 2019 | 7367 | 0.070 |
Why?
|
| Lorazepam | 1 | 2007 | 54 | 0.070 |
Why?
|
| Adolescent | 3 | 2014 | 8912 | 0.070 |
Why?
|
| Hypnotics and Sedatives | 1 | 2007 | 96 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 2279 | 0.070 |
Why?
|
| Biogenic Monoamines | 1 | 2006 | 18 | 0.070 |
Why?
|
| Catecholamines | 1 | 2006 | 73 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2009 | 1034 | 0.060 |
Why?
|
| Adaptation, Psychological | 1 | 2008 | 447 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 369 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2022 | 2358 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2007 | 1851 | 0.050 |
Why?
|
| Neuropsychological Tests | 3 | 2012 | 517 | 0.050 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2003 | 79 | 0.050 |
Why?
|
| Corticosterone | 1 | 2003 | 51 | 0.050 |
Why?
|
| Macaca mulatta | 2 | 2013 | 77 | 0.050 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2003 | 109 | 0.050 |
Why?
|
| Anisotropy | 2 | 2013 | 105 | 0.050 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 2002 | 41 | 0.050 |
Why?
|
| Exploratory Behavior | 1 | 2003 | 79 | 0.050 |
Why?
|
| Fibric Acids | 1 | 2022 | 12 | 0.050 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2002 | 59 | 0.050 |
Why?
|
| Altruism | 1 | 2002 | 24 | 0.050 |
Why?
|
| N-Methylaspartate | 1 | 2002 | 59 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 1174 | 0.050 |
Why?
|
| Mood Disorders | 1 | 2003 | 132 | 0.050 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2002 | 75 | 0.050 |
Why?
|
| Decision Trees | 1 | 2022 | 74 | 0.050 |
Why?
|
| Limbic System | 1 | 2002 | 106 | 0.050 |
Why?
|
| Photic Stimulation | 2 | 2012 | 229 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 536 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2003 | 216 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 236 | 0.050 |
Why?
|
| Metadata | 1 | 2021 | 1 | 0.050 |
Why?
|
| Checklist | 1 | 2022 | 76 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 211 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 320 | 0.050 |
Why?
|
| Sex Factors | 2 | 2014 | 1266 | 0.050 |
Why?
|
| Reward | 1 | 2002 | 201 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 2800 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2022 | 215 | 0.040 |
Why?
|
| Peptides | 1 | 2003 | 455 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2013 | 1040 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2020 | 110 | 0.040 |
Why?
|
| Genes, MHC Class I | 1 | 2019 | 14 | 0.040 |
Why?
|
| Genes, MHC Class II | 1 | 2019 | 29 | 0.040 |
Why?
|
| Colombia | 1 | 2019 | 8 | 0.040 |
Why?
|
| Keratosis, Seborrheic | 1 | 2019 | 2 | 0.040 |
Why?
|
| Israel | 1 | 2019 | 26 | 0.040 |
Why?
|
| Spain | 1 | 2019 | 34 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2012 | 782 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2019 | 76 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 88 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2017 | 1664 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2014 | 753 | 0.040 |
Why?
|
| Subarachnoid Space | 1 | 2018 | 7 | 0.040 |
Why?
|
| New York City | 1 | 2018 | 49 | 0.040 |
Why?
|
| Cognition | 1 | 2002 | 513 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2018 | 53 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2021 | 307 | 0.040 |
Why?
|
| Pain Threshold | 1 | 2018 | 55 | 0.040 |
Why?
|
| Aminolevulinic Acid | 1 | 2017 | 5 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2017 | 15 | 0.040 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2017 | 29 | 0.040 |
Why?
|
| Binding Sites | 1 | 2019 | 631 | 0.040 |
Why?
|
| Protein Array Analysis | 1 | 2017 | 32 | 0.040 |
Why?
|
| Fluorescence | 1 | 2017 | 104 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 103 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 331 | 0.040 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 2 | 2007 | 15 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2018 | 328 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2017 | 85 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2018 | 111 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2016 | 52 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 331 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 2 | 2012 | 296 | 0.030 |
Why?
|
| Anxiety | 2 | 2012 | 422 | 0.030 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2007 | 150 | 0.030 |
Why?
|
| Pituitary-Adrenal System | 2 | 2007 | 138 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 142 | 0.030 |
Why?
|
| Depression | 2 | 2014 | 943 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2017 | 239 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1140 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2017 | 307 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 700 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 132 | 0.030 |
Why?
|
| Molecular Imaging | 1 | 2015 | 45 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2015 | 82 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 62 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2019 | 1174 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 312 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2016 | 92 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 506 | 0.030 |
Why?
|
| Dissection | 1 | 2014 | 29 | 0.030 |
Why?
|
| Ependyma | 1 | 2014 | 1 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2017 | 384 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1738 | 0.030 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2014 | 5 | 0.030 |
Why?
|
| Microspheres | 1 | 2014 | 59 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 572 | 0.030 |
Why?
|
| Gray Matter | 1 | 2014 | 57 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2014 | 103 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 55 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2019 | 596 | 0.030 |
Why?
|
| Functional Neuroimaging | 1 | 2013 | 82 | 0.030 |
Why?
|
| Gadolinium DTPA | 1 | 2012 | 48 | 0.030 |
Why?
|
| Connectome | 1 | 2014 | 92 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 160 | 0.030 |
Why?
|
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2012 | 6 | 0.030 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2012 | 3 | 0.030 |
Why?
|
| Alleles | 1 | 2013 | 386 | 0.030 |
Why?
|
| Facial Expression | 1 | 2012 | 36 | 0.030 |
Why?
|
| Electromyography | 1 | 2012 | 184 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 92 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 86 | 0.020 |
Why?
|
| Emotions | 1 | 2013 | 244 | 0.020 |
Why?
|
| Microscopy | 1 | 2011 | 64 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 239 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2012 | 249 | 0.020 |
Why?
|
| Urban Population | 1 | 2012 | 255 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 1851 | 0.020 |
Why?
|
| Rape | 1 | 2012 | 180 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 183 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2010 | 15 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 240 | 0.020 |
Why?
|
| Extinction, Psychological | 1 | 2012 | 240 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 3705 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 852 | 0.020 |
Why?
|
| Violence | 1 | 2012 | 275 | 0.020 |
Why?
|
| Oxygen | 1 | 2012 | 386 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 562 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2012 | 705 | 0.020 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 1 | 2009 | 4 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2009 | 8 | 0.020 |
Why?
|
| Thrombopoietin | 1 | 2009 | 15 | 0.020 |
Why?
|
| Phorbol Esters | 1 | 2009 | 37 | 0.020 |
Why?
|
| K562 Cells | 1 | 2009 | 44 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1641 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2009 | 75 | 0.020 |
Why?
|
| Mitochondria | 1 | 2014 | 643 | 0.020 |
Why?
|
| Carcinogens | 1 | 2009 | 86 | 0.020 |
Why?
|
| Neurons | 2 | 2007 | 881 | 0.020 |
Why?
|
| Macrophages | 1 | 2012 | 647 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 2007 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2009 | 268 | 0.020 |
Why?
|
| RNA, Heterogeneous Nuclear | 1 | 2007 | 2 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 615 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1070 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 201 | 0.020 |
Why?
|
| Flumazenil | 1 | 2007 | 23 | 0.020 |
Why?
|
| Child | 1 | 2014 | 6405 | 0.010 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2003 | 85 | 0.010 |
Why?
|
| Cricetinae | 1 | 2003 | 262 | 0.010 |
Why?
|
| Phosphatidylinositols | 1 | 2002 | 40 | 0.010 |
Why?
|
| Xenopus laevis | 1 | 2002 | 60 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2002 | 144 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2002 | 160 | 0.010 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2002 | 51 | 0.010 |
Why?
|
| Oocytes | 1 | 2002 | 57 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 317 | 0.010 |
Why?
|
| Evoked Potentials | 1 | 2002 | 61 | 0.010 |
Why?
|
| Patch-Clamp Techniques | 1 | 2002 | 204 | 0.010 |
Why?
|
| Reaction Time | 1 | 2002 | 170 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 1293 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 765 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2002 | 270 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 1083 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 1447 | 0.010 |
Why?
|
| Dopamine | 1 | 2003 | 474 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2002 | 266 | 0.010 |
Why?
|
| Nucleus Accumbens | 1 | 2003 | 417 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2002 | 1200 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 1745 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2007 | 1242 | 0.010 |
Why?
|